Sancilio & Company Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Sancilio & Company Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10545
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:20
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Sancilio & Company Inc (SCI), a subsidiary of Sancilio Pharmaceuticals Company Inc is a drug development company that develops, manufactures and markets over the counter and generic prescription products. The company provides products such as omega-3, ludent sodium fluoride chewable tablets and multivitamin chewable tablets with fluoride and sodium fluoride drops. It offers services such as formulation development, analytical chemistry and packaging. SCI provides medicines that prevent common health problems and eliminate deficiencies. It develops Advanced Lipid Technologies using lipophilic compounds such as fatty acids, hormones, several vitamins, and many active pharmaceutical ingredients. SCI is headquartered in Riviera Beach, Florida, the US.

Sancilio & Company Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Sancilio & Company Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Sancilio & Company Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Sancilio & Company Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Sancilio & Company Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Sancilio & Company Inc, Medical Devices Deals, 2012 to YTD 2018 9
Sancilio & Company Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Sancilio & Company Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Sancilio Pharma Raises USD5 Million in Venture Financing 11
Sancilio & Company Raises USD20 Million in Venture Financing 12
Sancilio & Company Raises US$2 Million In Venture Financing 13
Equity Offering 14
Sancilio Pharma Withdraws IPO 14
Sancilio Pharma Raises USD20 Million in Private Placement of Series C Preferred Stock 15
Sancilio & Company Inc – Key Competitors 16
Sancilio & Company Inc – Key Employees 17
Sancilio & Company Inc – Locations And Subsidiaries 18
Head Office 18
Recent Developments 19
Product Approvals 19
Sep 19, 2017: Sancilio Pharmaceuticals Company, Receives Rare Pediatric Disease Designation from the U.S. Food and Drug Administration for Altemia a Treatment of Sickle Cell Disease (SCD) in Children 19
Appendix 20
Methodology 20
About GlobalData 20
Contact Us 20
Disclaimer 20

List of Tables
Sancilio & Company Inc, Pharmaceuticals & Healthcare, Key Facts 2
Sancilio & Company Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Sancilio & Company Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Sancilio & Company Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Sancilio & Company Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Sancilio & Company Inc, Medical Devices Deals, 2012 to YTD 2018 9
Sancilio & Company Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Sancilio Pharma Raises USD5 Million in Venture Financing 11
Sancilio & Company Raises USD20 Million in Venture Financing 12
Sancilio & Company Raises US$2 Million In Venture Financing 13
Sancilio Pharma Withdraws IPO 14
Sancilio Pharma Raises USD20 Million in Private Placement of Series C Preferred Stock 15
Sancilio & Company Inc, Key Competitors 16
Sancilio & Company Inc, Key Employees 17

List of Figures
Sancilio & Company Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Sancilio & Company Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Sancilio & Company Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Sancilio & Company Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Sancilio & Company Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Sancilio & Company Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Sancilio & Company Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Sancilio & Company Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Sancilio & Company Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Sancilio & Company Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Mmi Holdings Ltd.:企業の戦略・SWOT・財務分析
    Mmi Holdings Ltd. - Strategy, SWOT and Corporate Finance Report Summary Mmi Holdings Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Mondi Limited:企業の戦略・SWOT・財務情報
    Mondi Limited - Strategy, SWOT and Corporate Finance Report Summary Mondi Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Method Products, Inc.:企業の戦略的SWOT分析
    Method Products, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Bank Rossiya:企業の戦略・SWOT・財務分析
    Bank Rossiya - Strategy, SWOT and Corporate Finance Report Summary Bank Rossiya - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Chiesi USA Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Chiesi USA Inc (Chiesi USA), a subsidiary of Chiesi Farmaceutici S.p.A, is a specialty pharmaceutical company. It researches, develops, produces and commercializes therapies in cardiovascular, respiratory, neonatology, rare disease and special care therapeutics. The company's product portfol …
  • SGL Carbon SE:企業の戦略・SWOT・財務情報
    SGL Carbon SE - Strategy, SWOT and Corporate Finance Report Summary SGL Carbon SE - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Laing O’Rourke Plc:企業の戦略的SWOT分析
    Laing O'Rourke Plc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Southwestern Energy Co (SWN):企業の財務・戦略的SWOT分析
    Southwestern Energy Co (SWN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Theraclion SA (ALTHE):企業の財務・戦略的SWOT分析
    Summary Theraclion SA (Theraclion) is a medical device company that designs, markets, and develops high-intensity focused therapeutic ultrasound devices and equipment; and offers technical support services. The company offers echotherapy solution that combines HIFU therapy with ultrasound as a syste …
  • Egyptian Resorts Co
    Egyptian Resorts Co - Strategy, SWOT and Corporate Finance Report Summary Egyptian Resorts Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Copalis:戦略・SWOT・企業財務分析
    Copalis - Strategy, SWOT and Corporate Finance Report Summary Copalis - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Mitsubishi Tanabe Pharma Corp (4508):製薬・医療:M&Aディール及び事業提携情報
    Summary Mitsubishi Tanabe Pharma Corp (Mitsubishi Tanabe), a subsidiary of Mitsubishi Chemical Holdings Corp, identifies, develops, manufactures, procures and commercializes ethical drugs and over-the-counter (OTC) pharmaceutical products. The company develops ethical drugs for autoimmune disease, d …
  • Svenska Cellulosa Aktiebolaget:企業のM&A・事業提携・投資動向
    Svenska Cellulosa Aktiebolaget - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Svenska Cellulosa Aktiebolaget Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers a …
  • Full House Resorts Inc:戦略・SWOT・企業財務分析
    Full House Resorts Inc - Strategy, SWOT and Corporate Finance Report Summary Full House Resorts Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Etablissements Maurel & Prom SA Oil & Gas Exploration and Production Operations and Cost Analysis – 2017
    Etablissements Maurel & Prom SA Oil & Gas Exploration and Production Operations and Cost Analysis - 2017 Summary Etablissements Maurel & Prom SA Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comp …
  • Sa Sa International Holdings Limited (178):企業の財務・戦略的SWOT分析
    Sa Sa International Holdings Limited (178) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengt …
  • Lixil Group Corporation (5938):企業の財務・戦略的SWOT分析
    Lixil Group Corporation (5938) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Bank of Scotland Plc:企業のM&A・事業提携・投資動向
    Bank of Scotland Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Bank of Scotland Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A …
  • Vodafone Group Plc:企業の戦略・SWOT・財務情報
    Vodafone Group Plc - Strategy, SWOT and Corporate Finance Report Summary Vodafone Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Tsurumi Manufacturing Co Ltd (6351):企業の財務・戦略的SWOT分析
    Tsurumi Manufacturing Co Ltd (6351) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆